These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8325113)

  • 1. Use of amikacin and amoxicillin-clavulanic acid against Mycobacterium tuberculosis.
    Tamás F
    Chest; 1993 Jul; 104(1):328. PubMed ID: 8325113
    [No Abstract]   [Full Text] [Related]  

  • 2. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.
    Nadler JP; Berger J; Nord JA; Cofsky R; Saxena M
    Chest; 1991 Apr; 99(4):1025-6. PubMed ID: 1901260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.
    Cynamon MH; Palmer GS
    Antimicrob Agents Chemother; 1983 Sep; 24(3):429-31. PubMed ID: 6416162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activities of amoxicillin alone and in combination with clavulanic acid correlated with beta-lactamase production.
    Hsu LY; Chang SC; Luh KT; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Aug; 24(3):272-80. PubMed ID: 1818798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased beta-lactamase activity in Branhamella catarrhalis after exposure to amoxicillin and clavulanic acid.
    Bedenić B; Zagar Z
    J Chemother; 1994 Dec; 6(6):383-7. PubMed ID: 7699424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatotoxicity caused by amoxicillin, clavulanic acid or both?].
    Caballero Plasencia AM; Valenzuela Barranco M; Martín Ruiz JL; Guilarte López-Mañas J
    Gastroenterol Hepatol; 1997 Jan; 20(1):45-6. PubMed ID: 9072200
    [No Abstract]   [Full Text] [Related]  

  • 7. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 8. [The development of bacterial resistance and the role of clavulanic acid].
    Rolinson JN
    Antibiot Khimioter; 1992 Sep; 37(9):11-4. PubMed ID: 1444658
    [No Abstract]   [Full Text] [Related]  

  • 9. Clavulanic acid inhibits beta-lactamases.
    FDA Drug Bull; 1984 Dec; 14(3):25. PubMed ID: 6335441
    [No Abstract]   [Full Text] [Related]  

  • 10. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes.
    Fuglesang JE; Bergan T
    Infection; 1983; 11(6):329-35. PubMed ID: 6365790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) in the pediatric field].
    Iwai N; Taneda Y; Shibata M; Mizoguchi F; Katayama M
    Jpn J Antibiot; 1985 Feb; 38(2):342-58. PubMed ID: 3847522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming Beta-Lactamase-Based Antimicrobial Resistance by Nanocarrier-Loaded Clavulanic Acid and Antibiotic Cotreatments.
    Filby BW; Weldrick PJ; Paunov VN
    ACS Appl Bio Mater; 2022 Aug; 5(8):3826-3840. PubMed ID: 35819369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Appearance of Escherichia coli strain with high production of cephalosporinase during treatment with an amoxicillin and clavulanic acid combination].
    Aubert G; Peyle V; Dumont N; el Fassi M; Dorche G
    Ann Biol Clin (Paris); 1990; 48(7):449-54. PubMed ID: 2278408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of culture medium on the comparative in-vitro activity of amoxycillin and amoxycillin/clavulanic acid against Branhamella catarrhalis.
    Soriano F; Jiménez-Arriero M; Fernández-Roblas R
    J Antimicrob Chemother; 1987 Aug; 20(2):285-6. PubMed ID: 3117763
    [No Abstract]   [Full Text] [Related]  

  • 17. [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital].
    Bémer-Melchior P; Gilly L; Jugroot-Klotz K; Brun T; Névot P; Paul G
    Pathol Biol (Paris); 1995 Nov; 43(9):760-5. PubMed ID: 8746097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assessment of the effect of clavulanic acid at concentrations achieved in human serum on the bactericidal activity of amoxicillin at physiological concentrations against Staphylococcus aureus: implications for dosage regimens.
    Aguilar L; Martín M; Balcabao IP; Gómez-Lus ML; Dal-Ré R; Prieto J
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1403-5. PubMed ID: 9174210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
    Sorg TB; Cynamon MH
    J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.
    Casal M; Rodriguez F; Benavente M; Luna M
    Eur J Clin Microbiol; 1986 Aug; 5(4):453-4. PubMed ID: 3093225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.